Gene Marcial

Gene Marcial

InvestorPlace Contributor

Gene Marcial is a long-time observer of the investing world, having worked for The Wall Street Journal and BusinessWeek, where he wrote the closely followed “Inside Wall Street” column for 28 years. He now writes for MSN Money and contributes to Forbes. His most recent book is “Seven Commandments of Stock Investing,” published by FT Press.

Recent Articles

Xerox: Making Progress on the Comeback Path

By Gene Marcial, InvestorPlace Contributor

Its transition to a digital world is steadily taking shape. Wall Street isn't paying much attention, but XRX could be a long-term turnaround bet.

Cue the Biotech M&A Attack!

By Gene Marcial, InvestorPlace Contributor

A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.

ConocoPhillips’ Happy Divorce

By Gene Marcial, InvestorPlace Contributor

The spin-off of the refining operations is good news for investors.

Here Comes a Bidding War for Amylin

By Gene Marcial, InvestorPlace Contributor

Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share.

What the Bears Miss About Las Vegas Sands

By Gene Marcial, InvestorPlace Contributor

Investors under-appreciate the growth opportunities in Macau and Singapore.

Load More